The US Food and Drug Administration has asked Helius Medical Technologies, Inc. for additional information to support its de novo application for its portable neuromodulation stimulator (PoNS) as a therapy to treat walking difficulties related to multiple sclerosis (MS), the company announced on 19 October.
PoNS is a portable, non-invasive neuromodulation stimulator with an electrode array that delivers small electrical pulses to the user’s tongue. Research has consistently shown the tongue can be an effective...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?